Physician profile
Stephen A Boyd
NPI 1447542683
$9,088.97
in general payments reported to CMS, 2019-2025
49 companies · $2,125 in 2025
The $2,125 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $411 · 2021: $738 · 2022: $1,321 · 2023: $1,540 · 2024: $2,019 · 2025: $2,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,664 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,664.11 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,180.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $929.07 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $911.69 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $748.11 | 2019-2025 | |
| Amgen INC. | $710.99 | 2019-2025 | Repatha, Evenity, Otezla |
| Gilead Sciences, INC. | $670.54 | 2019-2025 | |
| Lilly USA, LLC | $594.35 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Viiv Healthcare Company | $451.06 | 2022-2025 | Apretude |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.11 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $254.09 | 2019-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $246.58 | 2022-2025 | |
| Glaxosmithkline, LLC. | $191.31 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amarin Pharma, INC. | $161.42 | 2019-2021 | |
| Exact Sciences Corporation | $157.21 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $144.87 | 2019-2025 | Freestyle Libre 3 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.